Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| While outpacing the growth of the overall market, we believe this product has additional room to grow in coming quarters |
| While there is still much work that lies ahead to build the company that we all believe we can be, I continue to be extremely impressed with the talent we have on board and the team's willingness to change the playbook and implement new thoughts and ideas |
| We believe this indicates that we're successfully increasing our market share in this important segment |
| As I have now completed my first two quarters at Minerva Surgical, I continue to be optimistic about the company's mission and future in meeting the distinct healthcare needs of women |
| As Todd mentioned, we were pleased with the revenue growth we experienced for Minerva ES and Symphion |
| In the ablation market, we were pleased that revenue from Minerva ES this past quarter increased 7% compared to the same period of 2022 |
| In my time in the field, what I'm hearing from our customers, echoing my prior conversations, is Minerva's technology provides outstanding solutions and outcomes and is solving real problems in uterine health |
| We're working to improve our gross margin through operational initiatives now that supply chains are stabilizing |
| And while it's still early days, I'm pleased with how the team is progressing |
| Despite the temporary distraction from a small reorganization this quarter, the commercial team has made progress with both customer retention and bringing on new customers in the ablation and tissue resection markets |
| Symphion revenue increased 7% this past quarter compared to the second quarter of 2022 and has increased 13% year-to-date during the first half of 2023 compared to the same period in 2022 |
| Last quarter, we completed a small reorganization of the commercial team to realign some of our operating costs, more effectively deliver our products to our customers and we have progressed our operational review of our production activities with the goal of improving costs and increasing our gross margins |
| Exclusive product efficiency and safety features unique to Symphion and our ability to compete with a full suite of products for abnormal uterine bleeding are continuing to show results |
| We believe that our Symphion System continues to outpace growth in the tissue resection market |
| People are our number one asset and I have enjoyed spending time with small groups of employees throughout the organization from all functions to dig deep to understand what makes our individuals tick and to listen and hear some wonderful thoughts and ideas to continue to grow Minerva Surgical |
| Turning quickly to some financial highlights, this past quarter, we reported revenues of $13.4 million, increasing from $13 million in the same period of 2022 and from $12.5 million in the first quarter of 2023 |
| Our commercial team has a deep level of talent that is responding to the changes introduced this past quarter to develop and deliver our products for the benefit of our customers and the women they serve, our investors and our employees |
| At the product level for the quarter, Minerva ES revenue was $6.1 million or 46% of total revenue, increasing 7% from $5.8 million in the second quarter of last year |
| Our entire team today is keenly focused on execution and delivering value to our customers, shareholders and other stakeholders |
| I've spent a great deal of my time and effort meeting with our customers and society partners, as well as key suppliers, contract manufacturers while digging into our overall operations to identify areas and opportunities for efficiency improvements |
| We have continued to evaluate both internal and external opportunities to drive commercial success and I look forward to updating you on those efforts when we have more tangible results to report |
| Joel? Joel Jung Thanks, Todd, and good afternoon, everyone |
| Statement |
|---|
| Additionally, we have experienced an increase in the transfer price for some of our products from our contract manufacturers, contributing to the challenges in our efforts to increase our overall gross margin |
| While we experienced a gross margin decline in the second quarter of 2023 compared to the same period of 2022, the gross margin for the first half of 2023 was 55.6% compared to 54.6% in the same period in 2022 |
| Our margins in the second quarter of 2023 were negatively impacted by a product mix shift away from Genesys HTA to Symphion which currently has a lower gross margin |
| On a non-GAAP basis, we reported negative $4.6 million in adjusted EBITDA for the second quarter of 2023 compared to negative $4.5 million in adjusted EBITDA in the second quarter of 2022 |
| Our gross margin in the second quarter of 2023 was 55.3%, which was a decrease from the gross margin of 59% reported in the second quarter of last year, but remaining relatively stable with the gross margin of 56% from the first quarter of this year |
| Our reported net loss for the second quarter of 2023 was $8.7 million compared to a net loss of $5.6 million in the second quarter of 2022 |
| Genesys HTA revenue was $3.6 million or 27% of total revenue in the second quarter of 2023, decreasing 8% from $3.9 million in the second quarter of last year .And Symphion revenue was $3.5 million or 26% of total revenue in the second quarter of 2023, increasing 7% from $3.3 million in the second quarter of last year |
Please consider a small donation if you think this website provides you with relevant information